Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (371-380 of 418) with videos related to

Pageof 42
Sort By:
Cancer Cell|December 19, 2015
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ DepletionKensuke Tateishi, Hiroaki Wakimoto, A John Iafrate, et al.
Cell Reports|November 16, 2017
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell LinesBradley Garman, Ioannis N Anastopoulos, Clemens Krepler, et al.
Nature Medicine|June 2, 2015
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFRMiguel Vizoso, Humberto J Ferreira, Paula Lopez-Serra, et al.
Cancer Discovery|February 6, 2023
Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor AlphaAvinash Sahu, Xiaoman Wang, Phillip Munson, et al.
Nature Genetics|February 10, 2015
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesLuping Lin, Amit J Sabnis, Elton Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Nature Communications|June 24, 2026
Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistanceSamuel J Wright, Izabella Zamora, Milan Parikh, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Nature Communications|October 27, 2017
Resistance to checkpoint blockade therapy through inactivation of antigen presentationMoshe Sade-Feldman, Yunxin J Jiao, Jonathan H Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 MonotherapyXue Bai, Jiani Hu, Allison Betof Warner, et al.
Pageof 42

Showing results (371-380 of 418) with videos related to

Sort By:
Pageof 42
Cancer Cell|December 19, 2015
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ DepletionKensuke Tateishi, Hiroaki Wakimoto, A John Iafrate, et al.
Cell Reports|November 16, 2017
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell LinesBradley Garman, Ioannis N Anastopoulos, Clemens Krepler, et al.
Nature Medicine|June 2, 2015
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFRMiguel Vizoso, Humberto J Ferreira, Paula Lopez-Serra, et al.
Cancer Discovery|February 6, 2023
Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor AlphaAvinash Sahu, Xiaoman Wang, Phillip Munson, et al.
Nature Genetics|February 10, 2015
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesLuping Lin, Amit J Sabnis, Elton Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Nature Communications|June 24, 2026
Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistanceSamuel J Wright, Izabella Zamora, Milan Parikh, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Nature Communications|October 27, 2017
Resistance to checkpoint blockade therapy through inactivation of antigen presentationMoshe Sade-Feldman, Yunxin J Jiao, Jonathan H Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 MonotherapyXue Bai, Jiani Hu, Allison Betof Warner, et al.
Pageof 42